Abstract
The importance of pharmacogenetics in medicine is growing with the identification of genetic variability by faster screening methods using automatic sequencers. A particularly interesting finding is that apart from environmental and psychological factors, drug response may be influenced by several biological factors as a result of genetic determinants leading to interindividual variability. Several mutations in genes coding for enzymes of the drug metabolizing system, as well as for neurotransmitter receptors or degrading enzymes and monoamine transport proteins, have been identified and investigated in psychiatry. But, despite the fact that some genetic polymorphisms of enzymes (mainly cytochrome P450 2D6) are well known, the application of pharmacogenetics as a therapeutic tool for improving patient care is rare. This review has three parts. In the first an overview is given of CYP450 characteristics and the genetic polymorphisms of interest to psychiatry. In the second the clinical implications of the CYP2D6 polymorphism are reviewed and in the third part other aspects on pharmacogenetic research in psychiatry are discussed. The aim of our review is to promote the application of pharmacogenetics in everyday clinical practice.
Keywords: Pharmacogenetics, metabolic polymorphism, CYP2D6, therapeutic implications
Current Pharmaceutical Design
Title: Pharmacogenetics and Drug Therapy in Psychiatry - The Role of the CYP2D6 Polymorphism
Volume: 13 Issue: 2
Author(s): P. Vandel, J. M. Talon, E. Haffen and D. Sechter
Affiliation:
Keywords: Pharmacogenetics, metabolic polymorphism, CYP2D6, therapeutic implications
Abstract: The importance of pharmacogenetics in medicine is growing with the identification of genetic variability by faster screening methods using automatic sequencers. A particularly interesting finding is that apart from environmental and psychological factors, drug response may be influenced by several biological factors as a result of genetic determinants leading to interindividual variability. Several mutations in genes coding for enzymes of the drug metabolizing system, as well as for neurotransmitter receptors or degrading enzymes and monoamine transport proteins, have been identified and investigated in psychiatry. But, despite the fact that some genetic polymorphisms of enzymes (mainly cytochrome P450 2D6) are well known, the application of pharmacogenetics as a therapeutic tool for improving patient care is rare. This review has three parts. In the first an overview is given of CYP450 characteristics and the genetic polymorphisms of interest to psychiatry. In the second the clinical implications of the CYP2D6 polymorphism are reviewed and in the third part other aspects on pharmacogenetic research in psychiatry are discussed. The aim of our review is to promote the application of pharmacogenetics in everyday clinical practice.
Export Options
About this article
Cite this article as:
Vandel P., Talon M. J., Haffen E. and Sechter D., Pharmacogenetics and Drug Therapy in Psychiatry - The Role of the CYP2D6 Polymorphism, Current Pharmaceutical Design 2007; 13 (2) . https://dx.doi.org/10.2174/138161207779313704
DOI https://dx.doi.org/10.2174/138161207779313704 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Interaction of Dietary Fibres with the Colon
Current Nutrition & Food Science Pharmacotherapy of Borderline Personality Disorder: A Systematic Review
Current Medicinal Chemistry New Insights Emerging from Recent Investigations on Human Group II Pyridoxal 5’-Phosphate Decarboxylases
Current Medicinal Chemistry Nanocrystal Approaches for Poorly Soluble Drugs and their Role in Development of Marketed Formulation
Drug Delivery Letters Acetaminophen (Paracetamol) Facilitated Extinction Lear ning in Contextual Fear Conditioned Rats
Letters in Drug Design & Discovery MRI Techniques for Describing Alterations in Material Properties of Cartilage and Intervertebral Disc Tissue
Current Medical Imaging Intra- and Interdomain Flexibility in Matrix Metalloproteinases: Functional Aspects and Drug Design
Current Pharmaceutical Design Cancer Metastasis: Characterization and Identification of the Behavior of Metastatic Tumor Cells and the Cell Adhesion Molecules, including Carbohydrates
Current Drug Targets - Cardiovascular & Hematological Disorders Acamprosate: A Prototypic Neuromodulator in the Treatment of Alcohol Dependence
CNS & Neurological Disorders - Drug Targets Treating Conformational Flexibility in Protein-Protein Docking
Current Physical Chemistry Cognition and Emotions in Recurrent Depressive Disorders - The Role of Inflammation and the Kynurenine Pathway
Current Pharmaceutical Design Bedside Balance Testing in Elderly People
Current Aging Science Cancer Treatment-Induced Cardiotoxicity: a Cardiac Stem Cell Disease?
Cardiovascular & Hematological Agents in Medicinal Chemistry Antioxidant Properties of Melatonin and its Potential Action in Diseases
Current Topics in Medicinal Chemistry Pharmacology and Toxicology of Cannabis Derivatives and Endocannabinoid Agonists
Recent Patents on CNS Drug Discovery (Discontinued) Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials
Current Drug Targets A Review of Current Animal Models of Osteoarthritis Pain
Current Pharmaceutical Biotechnology Transfer of Biologically Important Molecules Between Cells Through Gap Junction Channels
Current Medicinal Chemistry Beyond Mitochondria, What Would be the Energy Source of the Cell?
Central Nervous System Agents in Medicinal Chemistry Pain Perception and Management: Where do We Stand?
Current Molecular Pharmacology